Eagle Pharmaceuticals (EGRX) Reaches $55.46 After 6.00% Up Move; Profile of 6 Analysts Covering Carolina Financial (CARO)

November 14, 2017 - By Hazel Jackson

Among 7 analysts covering Carolina Financial Corporation (NASDAQ:CARO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Carolina Financial Corporation had 19 analyst reports since July

21, 2015 according to SRatingsIntel. The stock of Carolina Financial Corp (NASDAQ:CARO) earned “Buy” rating by Sandler O’Neill on Wednesday, November 9. The stock of Carolina Financial Corp (NASDAQ:CARO) has “Outperform” rating given on Tuesday, October 31 by Raymond James. The firm earned “Equal-Weight” rating on Friday, September 9 by Stephens. The firm has “Hold” rating by Stephens given on Monday, June 12. The rating was initiated by Brean Capital with “Hold” on Wednesday, November 30. The rating was upgraded by Brean Capital to “Buy” on Tuesday, June 13. On Monday, October 30 the stock rating was maintained by Brean Capital with “Buy”. The firm has “Buy” rating given on Friday, October 20 by Brean Capital. Stephens maintained the stock with “Hold” rating in Thursday, July 20 report. The company was maintained on Wednesday, August 2 by Brean Capital. See Carolina Financial Corp (NASDAQ:CARO) latest ratings:

10/11/2017 Broker: Brean Capital Rating: Buy New Target: $40.0 Maintain
30/10/2017 Broker: Brean Capital Rating: Buy Maintain
31/10/2017 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Downgrade
20/10/2017 Broker: Brean Capital Rating: Buy New Target: $37.0 Maintain
03/10/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $38.0 Maintain
02/08/2017 Broker: Brean Capital Rating: Buy Maintain
20/07/2017 Broker: Stephens Rating: Hold New Target: $34.0000 Maintain
07/07/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $38.0000 Maintain
13/06/2017 Broker: Brean Capital Rating: Buy Upgrade
12/06/2017 Broker: Stephens Rating: Hold Maintain

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is a huge mover today! About 143,913 shares traded. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 79.40% since November 14, 2016 and is uptrending. It has outperformed by 62.70% the S&P500.The move comes after 8 months positive chart setup for the $827.55 million company. It was reported on Nov, 14 by Barchart.com. We have $58.79 PT which if reached, will make NASDAQ:EGRX worth $49.65 million more.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma has $119 highest and $37.0 lowest target. $72.50’s average target is 30.72% above currents $55.46 stock price. Eagle Pharma had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25. The firm has “Buy” rating given on Monday, October 2 by RBC Capital Markets. The firm earned “Outperform” rating on Thursday, November 3 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Buy” on Friday, July 14. Mizuho initiated Eagle Pharmaceuticals Inc (NASDAQ:EGRX) rating on Wednesday, December 9. Mizuho has “Buy” rating and $112 target. As per Wednesday, July 29, the company rating was maintained by Piper Jaffray. Piper Jaffray maintained the shares of EGRX in report on Wednesday, August 9 with “Buy” rating. The firm has “Neutral” rating by Mizuho given on Wednesday, November 16. The company was downgraded on Monday, June 20 by Mizuho. Mizuho maintained Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Friday, February 26 with “Buy” rating.

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $827.55 million. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. It has a 8.94 P/E ratio. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on March, 7. They expect $0.95 EPS, down 73.01% or $2.57 from last year’s $3.52 per share. EGRX’s profit will be $14.18 million for 14.59 P/E if the $0.95 EPS becomes a reality. After $1.07 actual EPS reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -11.21% negative EPS growth.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>